AtheroGenics Gets Knocked Down
Drug developer AtheroGenics (AGIX) said Wednesday its failed heart-drug candidate showed signs it may be effective as an oral anti-diabetic drug The company is currently recruiting patients for a Phase III clinical trial on the drug candidate Wall St. seemed…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Drug developer AtheroGenics (AGIX) said Wednesday its failed heart-drug candidate showed signs it may be effective as an oral anti-diabetic drug
The company is currently recruiting patients for a Phase III clinical trial on the drug candidate
Wall St. seemed to think that the news put any recovery at the company almost out of reach. Its shares dropped 19% to $2.44. They have a 52-week high of $15.70.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.




